
Opinion|Videos|March 7, 2025
Perspectives and Future Directions in Biosimilar Health Care Delivery
A panelist discusses how managing biosimilars requires close collaboration between payers and health systems to optimize patient care and cost savings, while sharing insights about program implementation challenges across different care settings and emphasizing the importance of robust operational frameworks.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What would you like your payer colleagues to know about the use of biosimilars in the health system?
- What would you like to share with colleagues who might be starting or growing their biosimilar program?
- Please describe the differences in health care provider–administered vs retail settings with the use of biosimilars.
- What additional thoughts would you like to share on operationalizing biosimilars?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Langlara, third interchangeable biosimilar to Lantus, approved by FDA
2
FDA approves first treatment for chronic hepatitis D virus
3
Cancer patients taking GLP-1s less likely to develop advanced disease | ASCO 2026
4
Nubeqa edges Xtandi on cognitive side effects | ASCO 2026
5





















